Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	625	77-36-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clortalidone phthalamudine chlorphthalidolone chlorthalidone chlorthalidon chlortalidone	A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. Molecular weight: 338.76 Formula: C14H11ClN2O4S CLOGP: 0.45 LIPINSKI: 0 HAC: 6 HDO: 3 TPSA: 109.49 ALOGS: -3.81 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clortalidone
phthalamudine
chlorphthalidolone
chlorthalidone
chlorthalidon
chlortalidone

A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.

Molecular weight: 338.76
Formula: C14H11ClN2O4S
CLOGP: 0.45
LIPINSKI: 0
HAC: 6
HDO: 3
TPSA: 109.49
ALOGS: -3.81
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
25	mg	O
25	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.12 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	65 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.46 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	3.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.24 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	36 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	64 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.647		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	7.413		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	1.726	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	1.644	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	31.670	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	43.420	%	High	1
herg	hERG pIC50	4.095	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	1.072	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	3.141	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	39.180	%	High	1
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK	20
kinase-selectivity-class	AXL,BRAF,CDK9,EIF2AK3,GRK2,MAP2K6,MAPK1,MAPKAPK3,PDK1,PDK4,PIK3CD,SIK2,STK10,STK33,TEK	15
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	2.128		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	2.084		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	2.432		High	1
mppb	Mouse plasma protein binding (% unbound)	42.800		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	2.799		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		High	1
pppb	Pig plasma protein binding (% unbound)	47.120	%	High	1
rat-kpuu-brain	Rat brain Kpuu	0.018	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	1.081	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	91.480	%	High	1
rppb	Rat plasma protein binding (% unbound)	37.600	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	968.278	uM	High	1

Approvals:

Date	Agency	Company	Orphan
April 7, 1960	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	209.79	13.90	173	14442	133365	90480467
Hypokalaemia	102.91	13.90	116	14499	131000	90482832
Pneumonia viral	88.30	13.90	38	14577	8785	90605047
Lichen planopilaris	83.35	13.90	16	14599	184	90613648
Cardiac murmur	78.14	13.90	44	14571	18150	90595682
Presyncope	71.34	13.90	51	14564	31754	90582078
Milk-alkali syndrome	67.25	13.90	19	14596	1254	90612578
Breath sounds abnormal	65.50	13.90	37	14578	15349	90598483
Blood pressure increased	61.02	13.90	112	14503	197105	90416727
Renal impairment	54.93	13.90	76	14539	105345	90508487
Eosinophilia	44.77	13.90	37	14578	28496	90585336
Nasal congestion	40.28	13.90	58	14557	83356	90530476
Chronic obstructive pulmonary disease	39.61	13.90	54	14561	73775	90540057
Systemic infection	39.51	13.90	18	14597	4757	90609075
Synovitis	38.91	13.90	4	14611	329748	90284084
Maternal exposure during pregnancy	38.54	13.90	6	14609	360057	90253775
Stress cardiomyopathy	38.46	13.90	25	14590	13330	90600502
Myxoedema coma	35.25	13.90	9	14606	403	90613429
Pulmonary embolism	35.14	13.90	70	14545	130750	90483082
Drug interaction	34.99	13.90	111	14504	276342	90337490
Blood potassium decreased	33.66	13.90	40	14575	47687	90566145
Pericarditis	32.60	13.90	3	14612	270148	90343684
Systemic lupus erythematosus	30.80	13.90	10	14605	361886	90251946
Poor personal hygiene	30.61	13.90	8	14607	393	90613439
Treatment failure	30.47	13.90	6	14609	303922	90309910
Acute kidney injury	30.45	13.90	117	14498	320270	90293562
Diarrhoea infectious	29.25	13.90	10	14605	1239	90612593
Angle closure glaucoma	27.92	13.90	12	14603	2763	90611069
Exposure during pregnancy	27.84	13.90	3	14612	238407	90375425
Cough	26.70	13.90	124	14491	368838	90244994
Productive cough	26.67	13.90	46	14569	77017	90536815
Infusion related reaction	25.58	13.90	18	14597	416762	90197070
Hand deformity	25.55	13.90	8	14607	296354	90317478
Cockroach allergy	24.81	13.90	5	14610	75	90613757
Blood glucose increased	24.42	13.90	50	14565	95196	90518636
Irritable bowel syndrome	23.25	13.90	3	14612	207445	90406387
Catastrophic reaction	21.83	13.90	4	14611	35	90613797
Wound	21.51	13.90	11	14604	302969	90310863
Blood creatinine increased	21.17	13.90	49	14566	101337	90512495
Discomfort	20.95	13.90	9	14606	274326	90339506
Arthropathy	20.95	13.90	17	14598	366225	90247607
Joint abscess	20.51	13.90	6	14609	448	90613384
Hyperlactacidaemia	20.50	13.90	11	14604	4125	90609707
Syncope	20.30	13.90	57	14558	132606	90481226
Upper respiratory tract infection	19.50	13.90	55	14560	128263	90485569
Strabismus	19.47	13.90	9	14606	2459	90611373
Serotonin syndrome	19.25	13.90	27	14588	37860	90575972
Hepatic enzyme increased	19.11	13.90	18	14597	360718	90253114
Oedema peripheral	18.87	13.90	87	14528	257828	90356004
Renal failure	18.79	13.90	55	14560	130952	90482880
Nodal rhythm	18.75	13.90	8	14607	1810	90612022
Choroiditis	18.51	13.90	5	14610	279	90613553
Contraindicated product administered	18.13	13.90	15	14600	320124	90293708
Blister	17.02	13.90	10	14605	254988	90358844
Alopecia	16.89	13.90	34	14581	495037	90118795
Mite allergy	16.88	13.90	6	14609	834	90612998
Post procedural hypoparathyroidism	16.72	13.90	3	14612	23	90613809
Hyperkalaemia	16.52	13.90	34	14581	64930	90548902
Asthma	16.48	13.90	80	14535	242080	90371752
Nausea	16.26	13.90	260	14355	1110056	89503776
Hepatic cancer	16.21	13.90	10	14605	4871	90608961
Dehydration	16.04	13.90	68	14547	194379	90419453
Vascular access site pain	15.66	13.90	5	14610	501	90613331
Mean cell haemoglobin increased	15.57	13.90	9	14606	3896	90609936
Iron deficiency anaemia	15.32	13.90	19	14596	23643	90590189
Abdominal discomfort	15.26	13.90	34	14581	477294	90136538
Basophil count increased	15.04	13.90	6	14609	1145	90612687
Mean cell haemoglobin concentration increased	14.70	13.90	5	14610	610	90613222
Hypomagnesaemia	14.68	13.90	23	14592	35565	90578267
Delusional perception	14.56	13.90	4	14611	238	90613594
Anaemia of malignant disease	14.55	13.90	5	14610	629	90613203
Product monitoring error	14.31	13.90	9	14606	4535	90609297
Renal artery stenosis	14.30	13.90	7	14608	2170	90611662
Hypocalcaemia	14.27	13.90	25	14590	42343	90571489
Injury	14.25	13.90	7	14608	197342	90416490
Hypervitaminosis	14.22	13.90	3	14612	57	90613775
Ill-defined disorder	14.22	13.90	6	14609	184885	90428947

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	182.43	16.39	170	10293	101292	42509580
Hypokalaemia	144.11	16.39	128	10335	71593	42539279
Meningitis aseptic	101.32	16.39	39	10424	4443	42606429
Renal artery stenosis	85.62	16.39	29	10434	2288	42608584
Rectal prolapse	84.47	16.39	21	10442	547	42610325
Renal cyst haemorrhage	80.41	16.39	21	10442	669	42610203
Abdominal wall haemorrhage	71.29	16.39	18	10445	500	42610372
SARS-CoV-2 antibody test positive	70.56	16.39	17	10446	387	42610485
Vena cava injury	62.79	16.39	15	10448	329	42610543
Vascular anastomotic haemorrhage	58.96	16.39	14	10449	299	42610573
Chronic kidney disease	55.34	16.39	63	10400	47178	42563694
Carotid arteriosclerosis	55.24	16.39	21	10442	2311	42608561
Delayed graft function	52.75	16.39	21	10442	2614	42608258
Left ventricular hypertrophy	52.13	16.39	31	10432	9288	42601584
Vascular compression	50.82	16.39	13	10450	381	42610491
Aortic dilatation	50.51	16.39	18	10445	1651	42609221
Spinal osteoarthritis	48.86	16.39	29	10434	8657	42602215
Hyperparathyroidism secondary	48.78	16.39	18	10445	1824	42609048
Intraductal papillary mucinous neoplasm	47.98	16.39	13	10450	478	42610394
Perineal cyst	46.28	16.39	11	10452	236	42610636
Diverticulum intestinal	45.17	16.39	23	10440	5090	42605782
Aortic arteriosclerosis	45.14	16.39	23	10440	5097	42605775
Intervertebral disc space narrowing	44.95	16.39	15	10448	1130	42609742
Actinic keratosis	44.90	16.39	23	10440	5153	42605719
Mean cell volume increased	44.71	16.39	21	10442	3902	42606970
Hemiparaesthesia	43.27	16.39	10	10453	189	42610683
Blood 25-hydroxycholecalciferol decreased	42.69	16.39	11	10452	332	42610540
Fibrillary glomerulonephritis	41.52	16.39	8	10455	59	42610813
Hepatosplenomegaly	41.27	16.39	21	10442	4639	42606233
Choroidal effusion	39.95	16.39	10	10453	268	42610604
Spinal cord abscess	39.82	16.39	11	10452	435	42610437
Renin increased	37.52	16.39	9	10454	201	42610671
Presyncope	37.20	16.39	36	10427	22351	42588521
Spinal stenosis	35.02	16.39	21	10442	6385	42604487
Dizziness	34.89	16.39	137	10326	249117	42361755
Restless legs syndrome	34.05	16.39	24	10439	9590	42601282
Glycosylated haemoglobin increased	34.01	16.39	27	10436	12897	42597975
Hepatic steatosis	32.87	16.39	33	10430	21415	42589457
Acute kidney injury	30.22	16.39	173	10290	367164	42243708
Swelling of eyelid	29.32	16.39	13	10450	2115	42608757
Blood potassium increased	29.29	16.39	29	10434	18507	42592365
Vitamin D decreased	27.83	16.39	16	10447	4499	42606373
Squamous cell carcinoma of skin	26.06	16.39	23	10440	12703	42598169
Haemorrhoids	25.64	16.39	26	10437	17071	42593801
Febrile neutropenia	25.54	16.39	7	10456	185696	42425176
Arteriosclerosis	24.53	16.39	26	10437	17963	42592909
Bradycardia	24.09	16.39	60	10403	85424	42525448
Atrioventricular block first degree	22.51	16.39	16	10447	6475	42604397
Rhabdomyolysis	22.23	16.39	55	10408	77964	42532908
Amyloidosis	21.71	16.39	11	10452	2408	42608464
Myelitis transverse	21.07	16.39	9	10454	1338	42609534
Nocardiosis	20.84	16.39	14	10449	5176	42605696
Complications of transplanted kidney	20.45	16.39	14	10449	5336	42605536
Blood potassium decreased	20.24	16.39	25	10438	20359	42590513
Aortic valve incompetence	20.12	16.39	15	10448	6533	42604339
Oedema peripheral	19.97	16.39	76	10387	136000	42474872
Activated partial thromboplastin time prolonged	19.96	16.39	22	10441	15881	42594991
Glomerular filtration rate decreased	19.46	16.39	22	10441	16329	42594543
Renal impairment	19.09	16.39	65	10398	110163	42500709
Blood pressure fluctuation	19.07	16.39	28	10435	26880	42583992
Ventilation perfusion mismatch	18.97	16.39	5	10458	165	42610707
Gastrooesophageal reflux disease	18.79	16.39	37	10426	44986	42565886
Hyperkalaemia	18.14	16.39	52	10411	80406	42530466
Basal cell carcinoma	18.09	16.39	25	10438	22708	42588164
Benign prostatic hyperplasia	18.04	16.39	24	10439	21028	42589844
Fear	17.03	16.39	17	10446	10948	42599924
Choroidal detachment	17.01	16.39	6	10457	534	42610338
Off label use	16.45	16.39	91	10372	638244	41972628
Hyperglycaemic hyperosmolar nonketotic syndrome	16.42	16.39	8	10455	1610	42609262

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	406.07	13.21	338	21352	217315	110350294
Hypokalaemia	227.15	13.21	226	21464	182222	110385387
Presyncope	110.20	13.21	85	21605	48802	110518807
Renal artery stenosis	101.17	13.21	35	21655	3691	110563918
Renal cyst haemorrhage	83.04	13.21	21	21669	740	110566869
Lichen planopilaris	82.82	13.21	16	21674	154	110567455
SARS-CoV-2 antibody test positive	73.90	13.21	17	21673	398	110567211
Pneumonia viral	72.69	13.21	38	21652	11119	110556490
Acute kidney injury	72.66	13.21	281	21409	635149	109932460
Renal impairment	69.40	13.21	129	21561	188316	110379293
Abdominal wall haemorrhage	68.61	13.21	18	21672	735	110566874
Vena cava injury	65.79	13.21	15	21675	337	110567272
Vascular anastomotic haemorrhage	62.08	13.21	14	21676	299	110567310
Chronic kidney disease	60.94	13.21	75	21615	76216	110491393
Rectal prolapse	57.89	13.21	21	21669	2542	110565067
Left ventricular hypertrophy	56.06	13.21	34	21656	13210	110554399
Cardiac murmur	55.87	13.21	43	21647	24585	110543024
Milk-alkali syndrome	55.08	13.21	19	21671	1986	110565623
Carotid arteriosclerosis	54.29	13.21	21	21669	3036	110564573
Choroidal effusion	51.98	13.21	15	21675	875	110566734
Aortic dilatation	49.23	13.21	18	21672	2228	110565381
Perineal cyst	48.86	13.21	11	21679	233	110567376
Delayed graft function	47.57	13.21	21	21669	4236	110563373
Blood pressure increased	46.17	13.21	133	21557	258240	110309369
Vascular compression	44.89	13.21	13	21677	768	110566841
Angle closure glaucoma	44.79	13.21	19	21671	3480	110564129
Intervertebral disc space narrowing	44.57	13.21	16	21674	1880	110565729
Blood potassium decreased	44.51	13.21	54	21636	54060	110513549
Hepatic steatosis	43.91	13.21	51	21639	48780	110518829
Intraductal papillary mucinous neoplasm	43.67	13.21	13	21677	846	110566763
Aortic arteriosclerosis	43.54	13.21	27	21663	10911	110556698
Rhabdomyolysis	42.53	13.21	81	21609	120320	110447289
Hyperparathyroidism secondary	42.49	13.21	18	21672	3286	110564323
Bradycardia	42.39	13.21	94	21596	155423	110412186
Synovitis	42.16	13.21	3	21687	274089	110293520
Fibrillary glomerulonephritis	42.09	13.21	8	21682	70	110567539
Blood 25-hydroxycholecalciferol decreased	41.56	13.21	11	21679	465	110567144
Drug interaction	40.81	13.21	200	21490	499983	110067626
Actinic keratosis	40.38	13.21	22	21668	6991	110560618
Breath sounds abnormal	40.20	13.21	36	21654	25368	110542241
Mean cell volume increased	39.47	13.21	23	21667	8307	110559302
Spinal osteoarthritis	38.85	13.21	32	21658	20151	110547458
Hemiparaesthesia	38.36	13.21	10	21680	398	110567211
Spinal cord abscess	38.02	13.21	11	21679	648	110566961
Hepatosplenomegaly	37.89	13.21	21	21669	6898	110560711
Oedema peripheral	37.16	13.21	145	21545	328515	110239094
Maternal exposure during pregnancy	35.94	13.21	4	21686	254879	110312730
Blood potassium increased	35.52	13.21	38	21652	33211	110534398
Hyperkalaemia	34.69	13.21	80	21610	135716	110431893
Diverticulum intestinal	34.61	13.21	24	21666	11695	110555914
Renin increased	34.56	13.21	9	21681	357	110567252
Syncope	33.06	13.21	101	21589	202435	110365174
Febrile neutropenia	32.14	13.21	11	21679	316756	110250853
Pericarditis	32.03	13.21	3	21687	219111	110348498
Arteriosclerosis	31.33	13.21	31	21659	24736	110542873
Metabolic alkalosis	30.69	13.21	17	21673	5578	110562031
Basal cell carcinoma	30.63	13.21	41	21649	45229	110522380
Blood creatinine increased	30.60	13.21	92	21598	182797	110384812
Stress cardiomyopathy	30.30	13.21	25	21665	15781	110551828
Nasal congestion	29.75	13.21	62	21628	98220	110469389
Glycosylated haemoglobin increased	28.84	13.21	29	21661	23590	110544019
Myxoedema coma	28.76	13.21	9	21681	693	110566916
Chronic obstructive pulmonary disease	28.64	13.21	65	21625	109093	110458516
Squamous cell carcinoma of skin	28.45	13.21	25	21665	17178	110550431
Dizziness	28.00	13.21	233	21457	697960	109869649
Spinal stenosis	26.26	13.21	25	21665	19031	110548578
Treatment failure	25.84	13.21	11	21679	277223	110290386
Poor personal hygiene	25.63	13.21	8	21682	611	110566998
Vitamin D decreased	24.84	13.21	20	21670	12195	110555414
Dehydration	24.36	13.21	114	21576	279397	110288212
Systemic infection	24.16	13.21	18	21672	9801	110557808
Meningitis aseptic	24.08	13.21	18	21672	9852	110557757
Systemic lupus erythematosus	23.85	13.21	10	21680	254328	110313281
Benign prostatic hyperplasia	23.39	13.21	23	21667	18211	110549398
Hand deformity	23.20	13.21	7	21683	218499	110349110
Diarrhoea infectious	23.07	13.21	10	21680	1930	110565679
Infusion related reaction	22.43	13.21	25	21665	381137	110186472
Systolic hypertension	22.15	13.21	8	21682	956	110566653
Injury	22.14	13.21	4	21686	177261	110390348
Catastrophic reaction	21.84	13.21	4	21686	28	110567581
Hyperglycaemic hyperosmolar nonketotic syndrome	21.77	13.21	11	21679	2998	110564611
Complications of transplanted kidney	21.41	13.21	15	21675	7427	110560182
Amyloidosis	21.19	13.21	11	21679	3170	110564439
Restless legs syndrome	20.94	13.21	25	21665	24601	110543008
Swelling of eyelid	20.53	13.21	14	21676	6639	110560970
Hypotension	20.53	13.21	174	21516	523675	110043934
Eosinophilia	20.48	13.21	39	21651	57897	110509712
Iron deficiency anaemia	20.46	13.21	28	21662	31531	110536078
Sinus bradycardia	20.40	13.21	27	21663	29456	110538153
Aortic valve incompetence	20.28	13.21	17	21673	10964	110556645
Arthropathy	20.27	13.21	16	21674	287506	110280103
Irritable bowel syndrome	19.88	13.21	4	21686	164211	110403398
Liver injury	19.66	13.21	3	21687	150410	110417199
Hypocalcaemia	19.50	13.21	41	21649	65325	110502284
Activated partial thromboplastin time prolonged	19.50	13.21	23	21667	22345	110545264
Discomfort	19.25	13.21	9	21681	214698	110352911
Glomerular filtration rate decreased	19.24	13.21	26	21664	28930	110538679
Pulmonary embolism	19.07	13.21	88	21602	214386	110353223
Nocardiosis	19.04	13.21	14	21676	7472	110560137
Blood pressure inadequately controlled	18.80	13.21	14	21676	7619	110559990
Sleep disorder	18.32	13.21	8	21682	198636	110368973
Renal cyst	18.07	13.21	20	21670	18152	110549457
Myelitis transverse	18.03	13.21	9	21681	2392	110565217
Post procedural hypoparathyroidism	17.99	13.21	3	21687	11	110567598
Atrioventricular block	17.52	13.21	19	21671	16858	110550751
Atrial fibrillation	17.39	13.21	90	21600	229552	110338057
Blood glucose increased	17.07	13.21	61	21629	132435	110435174
Ill-defined disorder	16.70	13.21	5	21685	156848	110410761
Cockroach allergy	16.50	13.21	4	21686	118	110567491
Hypertensive crisis	16.37	13.21	22	21668	24350	110543259
Nausea	16.33	13.21	336	21354	1235354	109332255
Choroidal detachment	16.23	13.21	6	21684	766	110566843
Blood cholesterol increased	16.17	13.21	8	21682	184777	110382832
Ventilation perfusion mismatch	16.04	13.21	6	21684	791	110566818
Hypophagia	15.69	13.21	33	21657	52593	110515016
Hyperlactacidaemia	15.66	13.21	13	21677	8273	110559336
Blister	15.59	13.21	13	21677	227363	110340246
Haemorrhoids	15.14	13.21	26	21664	35646	110531963
Psoriatic arthropathy	15.11	13.21	10	21680	196751	110370858
Blood sodium decreased	15.05	13.21	27	21663	38292	110529317
Drug abuse	15.05	13.21	8	21682	177403	110390206
Nodal rhythm	15.03	13.21	9	21681	3414	110564195
Strabismus	14.85	13.21	9	21681	3490	110564119
Inappropriate antidiuretic hormone secretion	14.79	13.21	25	21665	33826	110533783
Myalgia	14.71	13.21	84	21606	222297	110345312
Treatment noncompliance	14.42	13.21	39	21651	72951	110494658
Drug intolerance	14.37	13.21	37	21653	406475	110161134
Rheumatoid arthritis	14.22	13.21	23	21667	299590	110268019
Intestinal angioedema	14.19	13.21	6	21684	1091	110566518
Vasoconstriction	14.12	13.21	6	21684	1104	110566505
Vascular access site pain	13.91	13.21	5	21685	590	110567019
Vertigo	13.86	13.21	43	21647	86827	110480782
Congenital aortic dilatation	13.49	13.21	3	21687	60	110567549
Therapy non-responder	13.48	13.21	7	21683	157300	110410309
Pulmonary artery dilatation	13.40	13.21	5	21685	655	110566954
Calcium ionised decreased	13.36	13.21	5	21685	661	110566948
Blood magnesium decreased	13.36	13.21	18	21672	19978	110547631
Asthenia	13.25	13.21	199	21491	688800	109878809
Angioedema	13.24	13.21	46	21644	98454	110469155
Therapy cessation	13.22	13.21	28	21662	44829	110522780
Hypervitaminosis	13.22	13.21	3	21687	66	110567543

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C03BA04	CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, EXCL. THIAZIDES Sulfonamides, plain
ATC	C03BB04	CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, EXCL. THIAZIDES Sulfonamides and potassium in combination
ATC	C03EA06	CARDIOVASCULAR SYSTEM DIURETICS DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION Low-ceiling diuretics and potassium-sparing agents
FDA PE	N0000175359	Increased Diuresis
FDA EPC	N0000175420	Thiazide-like Diuretic
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:145947	antiatherosclerotic agent
CHEBI has role	CHEBI:231911	renoprotective agent
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004232	Diuretics
MeSH PA	D045283	Natriuretic Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D049993	Sodium Chloride Symporter Inhibitors

Related Drugs by ATC class:

C03BA Sulfonamides, plain 10 drugs

clofenamide clopamide clorexolone fenquizone indapamide mefruside meticrane metolazone quinethazone xipamide

C03BB Sulfonamides and potassium in combination 4 drugs

clofenamide clopamide mefruside quinethazone

C03EA Low-ceiling diuretics and potassium-sparing agents 9 drugs

altizide bendroflumethiazide butizide cyclopenthiazide epitizide hydrochlorothiazide mebutizide metolazone trichlormethiazide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Edema	indication	267038008
Pulmonary Edema due to Chronic Heart Failure	indication
Peripheral Edema due to Chronic Heart Failure	indication
Diabetes insipidus	off-label use	15771004	DOID:9409
Calcium renal calculus	off-label use	427649000
Anuria	contraindication	2472002	DOID:2983
Suicidal thoughts	contraindication	6471006
Psoriasis	contraindication	9014002	DOID:8893
Peptic ulcer	contraindication	13200003	DOID:750
Hypercholesterolemia	contraindication	13644009
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Electroconvulsive therapy	contraindication	23835007
Complete atrioventricular block	contraindication	27885002
Depressive disorder	contraindication	35489007
Hyperuricemia	contraindication	35885006	DOID:1920
Anaphylaxis	contraindication	39579001
Hypokalemia	contraindication	43339004
Diabetes mellitus type 2	contraindication	44054006	DOID:9352
Conduction disorder of the heart	contraindication	44808001
Tear film insufficiency	contraindication	46152009
End stage renal disease	contraindication	46177005	DOID:784
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Chronic heart failure	contraindication	48447003
Sinus bradycardia	contraindication	49710005
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Cerebrovascular disease	contraindication	62914000	DOID:6713
Ulcerative colitis	contraindication	64766004	DOID:8577
Hypercalcemia	contraindication	66931009	DOID:12678
Hypochloremic alkalosis	contraindication	70134007
Oliguria	contraindication	83128009
Epilepsy	contraindication	84757009	DOID:1826
Cardiogenic shock	contraindication	89138009
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Asthma	contraindication	195967001	DOID:2841
Acute pancreatitis	contraindication	197456007	DOID:2913
Atrioventricular block	contraindication	233917008	DOID:0050820
Raynaud's phenomenon	contraindication	266261006
Calculus in biliary tract	contraindication	266474003
Pregnancy, function	contraindication	289908002
Severe chronic obstructive pulmonary disease	contraindication	313299006
Surgical procedure	contraindication	387713003
Chronic myocardial ischemia	contraindication	413844008	DOID:3393
First Degree Atrioventricular Heart Block	contraindication
Acutely Decompensated HF Requiring Parenteral Inotropic Therapy	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.63	acidic
pKa2	9.38	acidic
pKa3	13.47	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 40MG MEDOXOMIL;12.5MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	9387249	July 1, 2031	TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	9387249	July 1, 2031	TREATMENT OF HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Solute carrier family 12 member 3	Transporter	P55017	S12A3_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	6.46	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	6.71	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	7.64	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	8.35	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.04	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	8.05	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	8.55	CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	4.96	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	5.87	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	5.38	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Kd	5.56	WOMBAT-PK
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D	Enzyme	Q6IQ20	NAPEP_HUMAN	ALLOSTERIC MODULATOR	Kd	6.17	IUPHAR
Carbonic anhydrase 13	Enzyme		CAH13_MOUSE		Ki	7.82	CHEMBL

External reference:

ID	Source
4017887	VUID
N0000146240	NUI
D00272	KEGG_DRUG
2409	RXNORM
CHEBI:3654	CHEBI
KLT	PDB_CHEM_ID
CHEMBL1055	ChEMBL_ID
DB00310	DRUGBANK_ID
4364	MMSL
4432	MMSL
d00192	MMSL
002309	NDDF
387324004	SNOMEDCT_US
57893000	SNOMEDCT_US
C0008294	UMLSCUI
D002752	MESH_DESCRIPTOR_UI
2732	PUBCHEM_CID
7147	IUPHAR_LIGAND_ID
1125	INN_ID
4017887	VANDF
Q0MQD1073Q	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0213	TABLET	50 mg	ORAL	ANDA	24 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0222	TABLET	25 mg	ORAL	ANDA	24 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	0591-5782	TABLET	25 mg	ORAL	ANDA	17 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	0591-5783	TABLET	25 mg	ORAL	ANDA	17 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6900	TABLET	25 mg	ORAL	ANDA	21 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6900	TABLET	25 mg	ORAL	ANDA	21 sections
CHLORTHALIDONE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7583	TABLET	25 mg	ORAL	ANDA	20 sections
ATENOLOL AND CHLORTHALIDONE	HUMAN PRESCRIPTION DRUG LABEL	2	10135-733	TABLET	25 mg	ORAL	ANDA	21 sections
ATENOLOL AND CHLORTHALIDONE	HUMAN PRESCRIPTION DRUG LABEL	2	10135-734	TABLET	25 mg	ORAL	ANDA	21 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-128	TABLET	25 mg	ORAL	ANDA	16 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-129	TABLET	50 mg	ORAL	ANDA	16 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-936	TABLET	25 mg	ORAL	ANDA	16 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-937	TABLET	25 mg	ORAL	ANDA	16 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	21695-671	TABLET	25 mg	ORAL	ANDA	24 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	21695-743	TABLET	25 mg	ORAL	ANDA	18 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	21695-744	TABLET	25 mg	ORAL	ANDA	18 sections
TENORETIC	HUMAN PRESCRIPTION DRUG LABEL	2	24979-256	TABLET	25 mg	ORAL	NDA	23 sections
TENORETIC	HUMAN PRESCRIPTION DRUG LABEL	2	24979-257	TABLET	25 mg	ORAL	NDA	23 sections
Chlorthalidone	Human Prescription Drug Label	1	27241-216	TABLET	25 mg	ORAL	ANDA	20 sections
Chlorthalidone	Human Prescription Drug Label	1	27241-217	TABLET	50 mg	ORAL	ANDA	20 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	29300-333	TABLET	25 mg	ORAL	ANDA	19 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	29300-334	TABLET	50 mg	ORAL	ANDA	19 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	29300-400	TABLET	25 mg	ORAL	ANDA	17 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	29300-401	TABLET	25 mg	ORAL	ANDA	17 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	33261-942	TABLET	25 mg	ORAL	ANDA	18 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	43353-149	TABLET	25 mg	ORAL	ANDA	18 sections
Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	1	43353-922	TABLET	50 mg	ORAL	ANDA	24 sections
CHLORTHALIDONE	Human Prescription Drug Label	1	43598-167	TABLET	50 mg	ORAL	ANDA	21 sections
CHLORTHALIDONE	Human Prescription Drug Label	1	43598-170	TABLET	25 mg	ORAL	ANDA	21 sections
CHLORTHALIDONE	Human Prescription Drug Label	1	43598-719	TABLET	25 mg	ORAL	ANDA	21 sections

Ask DrugCentral

Try a sample question

chlortalidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: